Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00751231 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI
A Phase 2 study, sponsored by Portola Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 652
- Enrollment target
NCT00751231: Completed Phase 2 study, sponsored by Portola Pharmaceuticals.
NCT00751231 is a Phase 2 study that has completed, run by Portola Pharmaceuticals. The registered enrollment target is 652 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (390% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00751231, a Phase 2 study, has completed, sponsored by Portola Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 652 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI. After diagnostic angiography, patients scheduled for non-urgent PCI will be randomized to clopidogrel or to one of three dose levels of PRT060128.
Interventions
- DRUG clopidogrel
- DRUG PRT060128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 652 participants |
| Start Date | 2008-12 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
What the finished NCT00751231 record still lists
NCT00751231 is an interventional study that assigns participants to a tested intervention. The registered 652 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (390% higher).
The record links to 0 conditions, and to 2 interventions - of which clopidogrel is the first listed.
NCT00751231 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00751231 about?
NCT00751231 is a clinical study titled "A Phase 2 Safety and Efficacy Study of PRT060128, a Novel Intravenous and Oral P2Y12 Inhibitor, in Non-Urgent PCI". This is a multi-center, randomized, double-blind, triple-dummy, clopidogrel-controlled study of IV and oral PRT060128 compared to clopidogrel in patients undergoing non-urgent (including elective) PCI. After diagnostic angiography, patients scheduled for non-urgent PCI will be randomized to clopidog...
What is the current status of trial NCT00751231?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 652 participants. The study started on 2008-12. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00751231?
The interventions under investigation include: clopidogrel (DRUG), PRT060128 (DRUG).
Who is sponsoring clinical trial NCT00751231?
This trial is sponsored by Portola Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00751231's enrollment target sits among peer trials
652 50th of 2000 higher than 1,951 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06287346 · 652 participants
5-Years PMCF Study of Ceramic Dental Implants One-piece Versus Two-piece.
- NCT02934477 · 650 participants
Prospective Assessment of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis
- NCT04579120 · 650 participants
Neuroimaging in Healthy Aging and Senile Dementia (HASD_IND)
- NCT04875702 · 650 participants · Phase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia